4.6 Article

The Relationship Between Uric Acid Levels and Huntington's Disease Progression

期刊

MOVEMENT DISORDERS
卷 25, 期 2, 页码 224-228

出版社

WILEY
DOI: 10.1002/mds.22907

关键词

Huntington's disease; uric acid; progression

资金

  1. NIH, NINDS [NS R01-35284]
  2. General Clinical Research Centers [RR00052, RR00645, RR00042, RR00044, RR01066, RR07122]
  3. AstraZeneca
  4. Vitaline
  5. National Institutes of Health (NEI, NINDS, NIA)
  6. Michael J. Fox Foundation
  7. Medivation
  8. Neurosearch
  9. Pfizer
  10. National Institutes of Health
  11. Food and Drug Administration
  12. Spinal Muscular Atrophy Foundation
  13. Muscular Dystrophy Association
  14. Boehringer Ingelheim Pharmaceuticals, Inc.
  15. Neurosearch Sweden AB
  16. Employment University of Rochester

向作者/读者索取更多资源

Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE-HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. (C) 2010 Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据